PTSD / Trauma Open-Label Beyond MISTIC — Davis et al. 2023 Prospective SOF Ibogaine + 5-MeO-DMT (n=86)

Definition box

Definition: PTSD/trauma open-label series explicitly beyond Cherian MISTIC primary: Davis A.K., Xin Y., Sepeda N., & Averill L.A. (2023) *Open-label study of consecutive ibogaine and 5-MeO-DMT assisted-therapy for trauma-exposed male Special Operations Forces Veterans: prospective data from a clinical program in Mexico*, *The American Journal of Drug and Alcohol Abuse* 49(5):587–596 (doi: 10.1080/00952990.2023.2220874). Prospective program-evaluation surveys at baseline and 1-, 3-, and 6-month follow-up in n=86 trauma-exposed male SOF veterans completing a Mexico clinic sequence of oral ibogaine then inhaled 5-MeO-DMT. Authors reported significant improvements in self-reported PTSD, depression, anxiety, insomnia, post-concussive symptoms, life satisfaction, psychological flexibility, and cognitive functioning from baseline to 1 month, with a signal of durability toward 6 months. This is combination sequential therapy, open-label, self-report-heavy—not MISTIC (oral ibogaine + IV Mg for TBI), not an RCT, not a cure claim, and not psychoactive IV ibogaine infusion proof. Builds on—but is distinct from—Davis 2020 retrospective survey (/blog/davis-2020-ibogaine-5meo-veterans). Ibogaine is Schedule I / not FDA-approved. QTc/cardiac risk remains central.

Quotable answer (58 words)

Davis and colleagues’ 2023 American Journal of Drug and Alcohol Abuse prospective study of 86 SOF veterans found large self-reported PTSD and mood improvements after oral ibogaine then 5-MeO-DMT, with signals lasting toward six months. Open-label combination data are not MISTIC, not an RCT, and not psychoactive IV ibogaine infusion proof. Screen for QTc risk.

Why this spoke exists

MISTIC dominates headlines; Davis 2020 is already drafted. Searchers still need a named non-MISTIC prospective PTSD/trauma spoke that refuses to merge combination Mexico programs with Stanford oral+Mg TBI methods or with IV brand claims. Soft CTA: /safety-and-screening → /apply. Condition page: /ibogaine-for-ptsd.

What was studied

| Feature | Accurate description | |---------|----------------------| | Citation | Davis A.K., Xin Y., Sepeda N., Averill L.A. *Am J Drug Alcohol Abuse*. 2023;49(5):587–596. doi 10.1080/00952990.2023.2220874 | | Type | Prospective open-label clinical program evaluation (online surveys) | | N | 86 male SOF veterans (mean age ≈43; largely White/non-Hispanic) | | Sequence | Consecutive oral ibogaine then 5-MeO-DMT assisted-therapy in Mexico | | Timepoints | Baseline; 1, 3, 6 months post-treatment | | Headline domains | PTSD, depression, anxiety, insomnia, post-concussive symptoms, SWLS, flexibility, cognition | | What it is not | MISTIC; RCT; blinded; urine toxicology primary; FDA approval; psychoactive IV ibogaine monotherapy proof |

How it differs from MISTIC and from Davis 2020

| Program/paper | Design highlight | Route/combination | |---------------|------------------|-------------------| | Davis 2023 (this spoke) | Prospective multi-month surveys n=86 | Oral ibogaine + inhaled 5-MeO-DMT | | Davis 2020 | Retrospective 30-day pre/post survey n=51 | Same combination family | | Cherian MISTIC 2024 | Prospective clinician-rated disability/PTSD/depression/anxiety n≈30 | Oral ibogaine + IV Mg (no 5-MeO in primary protocol) |

Attribution rule: do not say “Stanford proved ibogaine+5-MeO cured PTSD” or “Davis 2023 is MISTIC.”

Key findings (no hype)

• Large pre→1-month improvements across trauma-relevant self-report scales (authors report significant p-values and effect-size statistics in-paper).
• Durability signal through 3–6 months for several domains—still open-label and attrition-sensitive.
• Combination therapy confounds attribution to ibogaine alone.
• Authors conclude potential for rapid robust change and call for controlled research.
• Psychological flexibility and acute meaningfulness themes appear in related predictor papers from the same program ecosystem—hypothesis-generating, not FDA endpoints.

Honest reading: Important prospective real-world trauma signal in a highly selected male SOF sample; weak external validity for civilians; zero cure language.

Cardiac / YMYL gap

Program-evaluation mental-health papers may under-detail continuous QTc tables. Ibogaine cardiac risk still applies (/blog/knuijver-2021-ibogaine-qtc-safety, /blog/ibogaine-qt-magnesium-protocol, /safety-and-screening). 5-MeO-DMT adds its own acute physiologic/psychiatric considerations—combination ≠ “safer because natural.”

Route honesty & entity clarity

Oral ibogaine (+ later 5-MeO) ≠ physician-supervised psychoactive IV ibogaine infusion. Supportive monitoring/IV fluids in clinic settings ≠ IV psychoactive brand entity (/blog/ibogaine-oral-vs-iv; /blog/ibogaine-vs-5-meo-dmt).

Limits and confounders

| Limit | Why it matters | |-------|----------------| | Open-label | Expectancy and regression to the mean | | Self-report surveys | No blinded CAPS-equivalent primary in this paper’s design class | | Combination therapy | Cannot isolate ibogaine vs 5-MeO vs therapy milieu | | Male SOF sample | Gender/occupation generalizability limited | | Mexico program setting | Not a U.S. FDA trial site | | Cardiac detail secondary | Incomplete risk picture alone |

What this does NOT prove for IV ibogaine infusion brand

| Claim | Status | |-------|--------| | “PTSD cured in 86 veterans” | False | | “Same as MISTIC / Stanford IV magnesium study” | False | | “Proves psychoactive IV ibogaine for PTSD” | False | | Labeled prospective oral-combination trauma signal? | Yes—with caveats |

Civilian translation caution

SOF veterans in a structured Mexico program are not the same population as civilian complex PTSD with untreated SUD, housing instability, or limited aftercare. Effect sizes in highly motivated, demographically narrow samples often shrink in broader care. For depression-adjacent reading see /ibogaine-for-depression—still without cure language.

Combination therapy attribution rule for SEO

Allowed: “In Davis et al. 2023’s prospective open-label evaluation of consecutive oral ibogaine and 5-MeO-DMT among 86 SOF veterans, self-reported PTSD and related symptoms improved from baseline to one month with signals toward six months—findings that remain uncontrolled and not psychoactive IV ibogaine monotherapy proof.”

Forbidden: “Ibogaine cures veteran PTSD with 86-person science” or “same as Stanford MISTIC IV treatment.”

Related alcohol/PTSD comorbidity note

A related prospective analysis from overlapping SOF program data examined co-occurring risky alcohol use and PTSD symptom trajectories after the same combination approach (published open-access discussions cite large reductions in alcohol use intensity alongside trauma scores). That comorbidity signal reinforces “whole-person” aftercare needs—it still does not isolate ibogaine monotherapy or validate psychoactive IV brand dosing.

One-sentence entity reminder

If a clinic quotes Davis 2023 while selling psychoactive IV ibogaine infusion, demand a route correction in writing—oral combination survey data do not transfer automatically.

Soft CTA

Trauma hope is not a cardiac plan. Start: /safety-and-screening → /apply.

FAQ

Which paper is this? Davis, Xin, Sepeda & Averill 2023, *Am J Drug Alcohol Abuse*, doi **10.1080/00952990.2023.2220874**.

Is it MISTIC? No. Different protocol family (ibogaine + 5-MeO; not oral+IV-Mg TBI primary).

Is it the 2020 Davis survey? No. This is prospective multi-month follow-up with larger n.

Was psychoactive IV ibogaine used? Not as the studied brand entity—oral ibogaine then inhaled 5-MeO-DMT.

Is it an RCT? No. Open-label program evaluation.

Does this erase cardiac risk? No.

Is ibogaine FDA-approved for PTSD? No. Schedule I; not FDA-approved.

Where should screening start? /safety-and-screening → /apply.

Sources (selected)

1. Davis A.K., Xin Y., Sepeda N., Averill L.A. *Am J Drug Alcohol Abuse*. 2023. doi: 10.1080/00952990.2023.2220874.
2. Davis A.K. et al. *Chronic Stress*. 2020. doi: 10.1177/2470547020939564.
3. Cherian K.N. et al. *Nat Med*. 2024. doi: 10.1038/s41591-023-02705-w.
4. Knuijver T. et al. *Addiction*. 2021. doi: 10.1111/add.15448.
5. 21 CFR 1308.11 — ibogaine Schedule I (United States).

Medical disclaimer

Educational research synopsis only—not medical, psychiatric, or legal advice, and not a guarantee of PTSD outcomes. Ibogaine can prolong the QTc interval and has been associated with serious cardiac events including torsades de pointes and death in some contexts. Ibogaine is Schedule I in the United States and is not FDA-approved for any indication. Provisional Mexico programs discussed on this site are not U.S. FDA clinics. Soft CTAs: /safety-and-screening, /apply.

Davis 2023 is an open-label combination oral-ibogaine + 5-MeO program evaluation—not a cure claim and not psychoactive IV ibogaine efficacy proof.